A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2002
12/19/2002	US20020193389 Method of inhibiting neoplastic cells with imidazoquinazoline derivatives
12/19/2002	US20020193387 As antimalarial agent
12/19/2002	US20020193386 Polymorphic form of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-alpha]pyrimidin-4-one and formulations thereof
12/19/2002	US20020193384 Using azoles for the preparation of topical formulation for the prevention of radiation-induced skin cancer
12/19/2002	US20020193380 Method for treatment of pain
12/19/2002	US20020193379 Decreasing the risk of or preventing neural tube disorders in a mammal by administering to a mammal D-chiro-inositol or a derivative or metabolite thereof
12/19/2002	US20020193378 Usable as tranquillisers and hypnotics
12/19/2002	US20020193377 Quinazolines as MMP-13 inhibitors
12/19/2002	US20020193376 Administering compounds containing fused, 6-, 5-membered bicyclic heteroaromatic rings containing nitrogen as one of the two bridging atoms for decreasing intraocular pressure in an animals including humans
12/19/2002	US20020193375 Heterocyclic derivatives which inhibit factor Xa
12/19/2002	US20020193373 Therapy of disorders of the outer retina by administering a pharmaceutically effective amount of a beta -adrenoceptor antagonist
12/19/2002	US20020193371 Using compound which inhibits expression of the gene TPT1 (translationally controlled tumor protein encoding histamine releasing factor) or of the products which it controls, for producing a drug which is intended for treating cancer
12/19/2002	US20020193370 For therapy and prophylaxis of ophthalmic, otic or nasal infections and attendant inflammation
12/19/2002	US20020193369 Antifungal compounds and uses therefor
12/19/2002	US20020193368 Use of potassium channel openers for the treatment of insulitis
12/19/2002	US20020193367 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives
12/19/2002	US20020193366 Azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]-quinoline as 5-HT1A antagonists
12/19/2002	US20020193364 For therapy of central nervous system (CNS) diseases
12/19/2002	US20020193363 Administering ruthenium complexs for modulating inflammation associated with trauma
12/19/2002	US20020193362 Anti-tumor composition
12/19/2002	US20020193360 For enhancing cognition or in the treatment of diseases of cognitive dysfunction including but not limited to Alzheimer's Disease (AD), mild cognitive impairment, age-related cognitive decline, vascular dementia, Parkinson's disease
12/19/2002	US20020193359 Androgen as a male contraceptive and non-contraceptive androgen replacement
12/19/2002	US20020193358 Using once-a-month injection that contains estrogenic and gestagenic components as an active ingredient for the production of a pharmaceutical agent for contraception and simultaneous hormone replacement therapy
12/19/2002	US20020193357 Liver X receptor agonists
12/19/2002	US20020193356 Means and method for hormonal contraception
12/19/2002	US20020193354 7, 9-substituted tetracycline compounds
12/19/2002	US20020193353 2-hydroxymethylcyclopropylidenemethylpurines and -pyrimidines as antiviral agents
12/19/2002	US20020193349 For use in formulation for oral cavity, cosmetics
12/19/2002	US20020193341 Vitamin supplement composition
12/19/2002	US20020193339 Antiviral agent for use in treatment of cancer
12/19/2002	US20020193333 For immunization for the therapy of diseases with or without combination chemotherapy
12/19/2002	US20020193323 Compositions and methods for promoting a healthy cardiovascular system and enhancing blood flow
12/19/2002	US20020193322 Adding trisubstituted salt of glycyrrhizic acid to aqueous soltuion of first physiologically acceptable compound of an acidic nature, and second physiologically acceptable compound of a basic nature
12/19/2002	US20020193321 Shelf life
12/19/2002	US20020193318 Administering compound that binds human serum albumin (HSA) to increase free drug levels of the camptothecin compound during anti-topoisomerase I-based therapy in human
12/19/2002	US20020193317 Using smilagenin, prazerigenin, an astragaloside, tigogenin, ruscogenin, hecogenin and diosgenin in manufacture of medicament for therayp of condition characterised by deficiency in postsynaptic membrane-bound receptor number
12/19/2002	US20020193316 Caloporoside derivatives, methods of their preparation and use
12/19/2002	US20020193315 Having inhibitory activity against diacylglycerol acyltransferase and useful for therapy and prophylaxid of disease of humans such as obesity or hyperlipidemia which is caused by accumulation of triacylglycerol
12/19/2002	US20020193312 For therapy of asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, tissue transplantation, tumor metastasis, meningitis, encephalitis, stroke, nephritis
12/19/2002	US20020193311 Novel cytostatic conjugates with integrin ligands
12/19/2002	US20020193310 For therapy of hyperglycemic disorders
12/19/2002	US20020193307 Antagonism of endothelin actions
12/19/2002	US20020193291 Treating NIDDM with RXR agonists
12/19/2002	US20020193290 Methods for fine powder formation
12/19/2002	US20020192842 Method of treating certain indications associated with hyperglycemia
12/19/2002	US20020192826 Recombinant AAV vector-based transduction system and use of same
12/19/2002	US20020192800 Nucleotide sequences coding polypeptide for use in the prevention, diagnosis and treatment of thrombosis, emphysema and liver disorders
12/19/2002	US20020192770 Beta-glucan products and extraction processes from cereals
12/19/2002	US20020192737 Detecting modulators of oxidoreductases; obtain sample, incubate with modulator, detect signal, monitor adjustment in enzyme activity
12/19/2002	US20020192729 Apoptosis protein for use in the diagnosis and treatment of cell proliferative disorders
12/19/2002	US20020192728 Neuroblastoma cell lines expressing the alpha2delta subunit of calcium channels and methods therefore
12/19/2002	US20020192723 Protein for use in the diagnosis and treatment of autoimmune disease
12/19/2002	US20020192709 Detection of modulators of receptor binding activity; obtain sample containing receptor, incubate with modulator, monitor adjustment of binding activity of receptor
12/19/2002	US20020192706 Nucleotide sequences coding polypeptides for use treatment of cell proliferation disorders
12/19/2002	US20020192699 Genes and gene expression products that are differentially regulated in prostate cancer
12/19/2002	US20020192695 Detection of modulator of tumor suppressor activity; obtain sample of polypeptide, incubate with modulator, monitor adjustment in polypeptide activity
12/19/2002	US20020192682 Polynucleotides and polypeptides of the IFNalpha-2 gene
12/19/2002	US20020192643 Nucleotide sequences coding polypeptide for use in the treatment of cell proliferation or inflammatory disorders
12/19/2002	US20020192354 Calorically dense liquid oral supplement
12/19/2002	US20020192317 Preventive, alleviative or remedy for hypertension
12/19/2002	US20020192307 Method and composition for enhancing sexual desire
12/19/2002	US20020192306 Gastric acid secretion
12/19/2002	US20020192303 Treatment of side effects associated with alcohol consumption
12/19/2002	US20020192302 Transdermal and topical administration of antidepressant drugs using basic enhancers
12/19/2002	US20020192301 Transdermal and topical administration of antihypertensive agents using basic enhancers
12/19/2002	US20020192300 Transdermal and topical administration of antipsychotic agents using basic enhancers
12/19/2002	US20020192299 Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
12/19/2002	US20020192294 Induced phase transition method for the production of microparticles containing hydrophobic active agents
12/19/2002	US20020192292 Microparticulate form of a tetrahydropyridin derivative
12/19/2002	US20020192290 Composition with sustained release of levodopa and carbidopa
12/19/2002	US20020192289 Polymer gel for cancer treatment
12/19/2002	US20020192288 Methods and compositions for treating pain of the mucous membrane
12/19/2002	US20020192282 Multilayer pharmaceutical product for release in the colon
12/19/2002	US20020192281 Beta-lactam antibiotic-containing tablet and production thereof
12/19/2002	US20020192280 Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
12/19/2002	US20020192279 Method for producing antibiotic composites
12/19/2002	US20020192277 Controlled release hydrocodone formulations
12/19/2002	US20020192272 Metronidazole pledgets
12/19/2002	US20020192264 Materials and methods for the treatment or prevention of obesity
12/19/2002	US20020192262 1'-Acetoxychavicol acetate for tuberculosis treatment
12/19/2002	US20020192253 Peeling composition
12/19/2002	US20020192243 Transdermal and topical administration of drugs for the treatment of Alzheimer's disease using basic enhancers
12/19/2002	US20020192242 Bone disorders; drug delivery; mixture of bone density regulator and base
12/19/2002	US20020192241 Methods of using kavalactone compositions
12/19/2002	US20020192227 Vaccines against cancer and infectious diseases
12/19/2002	US20020192225 Methods of identifying bacterial genes that are incompatible with bacterial pathogenicity, and the use of such genes, such as cadA, to reduce pathogenicity in a bacteria or to combat pathogenic bacterial infections
12/19/2002	US20020192203 Sterol absorption inhibitor compositions
12/19/2002	US20020192202 Probiotic compounds derived from lactobacillus casei strain KE01
12/19/2002	US20020192201 Crohn's disease treatment methods
12/19/2002	US20020192193 Antigen presenting cells, a process for preparing the same and their use as cellular vaccines
12/19/2002	US20020192192 Antigen presenting cells, a process for preparing the same and their use as cellular vaccines
12/19/2002	US20020192184 Use of stabilized oligonucleotides for preparing a medicament with antitumor activity
12/19/2002	US20020192182 Polysaccharide-based polymerizable hydrogels
12/19/2002	US20020192171 Method for preventing malodor
12/19/2002	US20020192167 Use of sunscreen combinations which comprise, as essential constituent, 2-(4-alkoxyanilinomethylene) malonic dialkyl esters as photosatble uv filters in cosmetic and pharmaceutical preparations
12/19/2002	US20020192161 Animal model for evaluating analgesics
12/19/2002	US20020189610 Pharmaceutical compositions containing an ipratropium salt and a betamimetic
12/19/2002	US20020189608 Enhancing athletic performance through the administration of peppermint odor
12/19/2002	DE4447770C2 Verfahren zur Herstellung von liposomal verkapseltem Taxol Process for the preparation of liposomally encapsulated Taxol
12/19/2002	DE10129940A1 Medicament used for treating central nervous system disorders e.g. psychosis, depression or neurological disorders, comprises new or known 4-phenylsulfonyl-oxazole-5-amine derivative which are serotonin 5-HT6 receptor ligands

1 ... 5615 5616 5617 5618 5619 5620 5621 5622 5623 5624 5625 5626 5627 5628 5629 5630 5631 5632 5633 5634 5635 ... 7860